Array Biopharma Inc. (ARRY)

Trade ARRY now with
10/30/2018 8:03:28 AM Array BioPharma Q1 Net Loss Narrows To $24.8 Mln Or $0.12/shr From $38.0 Mln Or $0.22/shr Last Year
9/13/2018 8:01:33 AM Array BioPharma Announces Publication Of Detailed Overall Survival Results From COLUMBUS Trial
8/14/2018 8:03:16 AM Array BioPharma Q4 Net Loss $52.4 Mln Or $0.25/shr Vs. Loss $29.6 Mln Or $0.17/shr Prior Year
8/10/2018 8:01:57 AM Array BioPharma Names Carrie Cox Chairman
8/7/2018 8:02:53 AM Array BioPharma Gets FDA Breakthrough Therapy Designation For BRAFTOVI In Combination With MEKTOVI And Cetuximab
7/27/2018 8:35:13 AM Array BioPharma Says BRAFTOVI + MEKTOVI Receives Positive CHMP Opinion For Advanced BRAF-mutant Melanoma
7/16/2018 6:47:42 AM New Drugs Approved In June
7/13/2018 8:07:50 AM Array: NCCN Guidelines Recommend BRAFTOVI With MEKTOVI As Category 1 Treatment Option For BRAF-mutant Melanoma
6/27/2018 2:28:07 PM Array BioPharma Announces FDA Approval Of BRAFTOVI In Combination With MEKTOVI
6/23/2018 7:40:34 AM Array BioPharma Reports 62% Overall Survival At One Year From Phase 3 BEACON CRC Trial
6/4/2018 8:01:29 AM Array BioPharma Announces Additional Median Overall Survival Results Of Encorafenib And Binimetinib